Literature DB >> 34149253

Time in Range as a Research Outcome Measure.

Joseph G Timmons1,2, James G Boyle2,3, John R Petrie1,2.   

Abstract

Time in range (TIR) is gaining ground as an outcome measure in type 1 diabetes trials. However, inclusion of TIR raises several issues for trial design. In this article, the authors begin by defining TIR and describing the current international consensus around TIR targets. They then expand on evidence for the validity of TIR as a primary clinical trial outcome before concluding with some practical, ethical, and logistical implications.
© 2021 by the American Diabetes Association.

Entities:  

Year:  2021        PMID： 34149253      PMCID： PMC8178718          DOI： 10.2337/ds20-0097

Source DB:  PubMed          Journal:  Diabetes Spectr        ISSN： 1040-9165


  34 in total

Review 1.  Positioning time in range in diabetes management.

Authors:  Andrew Advani
Journal:  Diabetologia       Date:  2019-11-07       Impact factor: 10.122

Review 2.  Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2016-11-21       Impact factor: 19.112

3.  Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US.

Authors:  Earl S Ford; Catherine C Cowie; Chaoyang Li; Yehuda Handelsman; Zachary T Bloomgarden
Journal:  J Diabetes       Date:  2011-03       Impact factor: 4.006

4.  Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials.

Authors:  Roy W Beck; Richard M Bergenstal; Tonya D Riddlesworth; Craig Kollman; Zhaomian Li; Adam S Brown; Kelly L Close
Journal:  Diabetes Care       Date:  2018-10-23       Impact factor: 19.112

5.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

6.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

Review 7.  6. Glycemic Targets: Standards of Medical Care in Diabetes-2020.

Authors: 
Journal:  Diabetes Care       Date:  2020-01       Impact factor: 19.112

8.  Preserved C-peptide secretion is associated with fewer low-glucose events and lower glucose variability on flash glucose monitoring in adults with type 1 diabetes.

Authors:  Fraser W Gibb; John A McKnight; Catriona Clarke; Mark W J Strachan
Journal:  Diabetologia       Date:  2020-02-07       Impact factor: 10.122

9.  Practical estimation of cloud storage costs for clinical genomic data.

Authors:  Niklas Krumm; Noah Hoffman
Journal:  Pract Lab Med       Date:  2020-05-15

10.  Time in Range in Relation to All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes: A Prospective Cohort Study.

Authors:  Jingyi Lu; Chunfang Wang; Yun Shen; Lei Chen; Lei Zhang; Jinghao Cai; Wei Lu; Wei Zhu; Gang Hu; Tian Xia; Jian Zhou
Journal:  Diabetes Care       Date:  2020-10-23       Impact factor: 17.152
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.